$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
The efficacy of gefitinib has been confirmed and has been included in domestic medical insurance
2025-10-19 11:44:20
Check Details
Erlotinib prolongs patient survival by up to 11 months!
2025-10-19 11:44:20
Check Details
The third generation of EGFR-targeted drugs, a detailed explanation of osimertinib in one article
2025-10-19 11:44:20
Check Details
Compared with previous generation drugs, dacomitinib extends the survival period by more than half!
2025-10-19 11:44:20
Check Details
Compared with the previous generation of drugs, afatinib has more significant efficacy_ Kanghule
2025-10-19 11:44:20
Check Details
Tepotinib is approved for marketing in China, which is of great significance
2025-10-19 11:44:20
Check Details
How to solve the problem of hyperlipidemia in patients taking lorlatinib?
2025-10-19 11:44:20
Check Details
The third generation ALK inhibitor, how good is lorlatinib? _ Kanghule
2025-10-19 11:44:20
Check Details
A potential stock for multi-faceted cancer killing—ramucirumab
2025-10-19 11:44:20
Check Details
How effective is cabozantinib in treating renal cancer?
2025-10-19 11:44:20
Check Details
What kind of drug is gefitinib? What are the adverse reactions of gefitinib?
2025-10-19 11:44:20
Check Details
How effective is erlotinib in treating non-small cell lung cancer?
2025-10-19 11:44:20
Check Details
1
2
...
10061
10062
10063
10064
10065
10066
10067
...
10234
10235
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lyrfigtu (lirafugratinib) for Pretreated FGFR2 Cholangiocarcinoma: 70mg Daily, REFOCUS Efficacy, Ocular and Phosphate Monitoring
2
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
3
Belumosudil for cGVHD: 200mg with Food, Pregnancy Contraception, Liver Monitoring, Drug Interactions
4
Elagolix GnRH Antagonist for Endometriosis Pain: Mechanism, Dosing, Bone and Mood Safety
5
Diazoxide Oral Suspension Inadequate Response: Glucose-Based Titration, Stop at 2–3 Weeks, Re-evaluate Hypoglycemia Cause
6
Ambrisentan Adjunct for IgA Nephropathy Proteinuria: ETA Mechanism, Real-World Evidence, Safety Monitoring
7
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
8
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
9
Lemborexant for Insomnia: Dual Orexin 5/10mg, 7-Hour Bedtime, 7–10-Day Review and Safety
10
Fayuvi (rebisufligene etisparvovec-hopf) for MPS IIIA: AAV9 Single Infusion, Weight-Based Dose, Steroids, Liver/Platelet Monitoring
11
Trelagliptin Once-Weekly DPP-4 for Type 2 Diabetes: Dosing, Renal Adjustment, Discontinuation
12
Orforglipron (Foundayo) vs Metformin: Oral GLP-1 Weight Loss and T2D Use